Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.

Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.

Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinic workflows, safety checks, and at-home dosing potential for on-body isatuximab.

Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.

For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker testing, and support.

In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.

Marieta Branis, APN, discusses individualized breast cancer care, monitoring for ADC and oral therapy toxicities, younger patients, and survivorship.

In a randomized trial, 73% of relatives offered navigation completed genetic testing within 6 months vs 51% of those who received a family letter.